Pfizer Inc.’s R&D efforts in non-alcoholic steatohepatitis (NASH) have been going on for about six and a half years, but the pharma only presented its first clinical data for a NASH candidate at the 2018 International Liver Conference in April. The company is advancing three clinical candidates for NASH, with a diabetes candidate also possibly offering potential in the unmet medical need, with a focus on reducing fat in the liver and the hope that other aspects of the disease will show benefit as well.
“Because we're operating [the program] out of a metabolic unit and that's our bias as well as our expertise, we made the decision to really focus on the metabolic aspects...